FOR IMMEDIATE RELEASE

Contact: Lisa Romero
Communications and Development Manager
520-547-3440
lromero@c-path.org
www.c-path.org

GOVERNOR BREWER AWARDS $2.2 MILLION TOWARDS CREATION OF NEW BIOMEDICAL RESEARCH RESOURCE IN ARIZONA

Science Foundation Arizona selects Tucson-based Critical Path Institute and collaborator, Roche’s Ventana Medical Systems, to develop innovative national resource for clinical research standardization

Phoenix, Arizona, October 28, 2010 – (Tucson, AZ) Governor Jan Brewer today announced that she would dedicate $2.2 million of Arizona’s share of federal stimulus funding toward a new program expected to establish the state as a national resource for setting standards and best practices for new diagnostic medical tests and clinical research that translates science into healthcare.

This effort will be led by Tucson-based Critical Path Institute (C-Path) who, along with industry partners, Roche’s Ventana Medical Systems and other major pharmaceutical companies, will focus on major diseases including lung cancer, Alzheimer’s, and kidney disease.

The money was awarded to Science Foundation Arizona (SFAz), who, after rigorous review, selected C-Path’s application for funding. C-Path’s vision is to work with research leaders across Arizona to create a biosignatures laboratory that scientists around the world will access to learn how to perform and interpret new diagnostic tests reliably. These standards will create the opportunity to more accurately identify characteristics (biomarkers) of patients likely to respond to precisely targeted therapies, thus enabling individual, patient-centered medical treatments (personalized medicine) in the future.

“Bioscience industries are fast-growing employment sectors that have the potential to create high-quality jobs - the very kind we need in our state,” said Governor Brewer. “This collaborative effort between our excellent universities, nonprofit research entities, and strong base of companies already in Arizona will put us on the international map as a leader in medical
treatment breakthroughs and prevention of major diseases. Critical Path Institute and Roche’s Ventana Medical Systems are both proven experts in their respective areas and will lead much needed efforts to significantly improve public health outcomes.”

C-Path and Ventana will work under a cooperative research and development agreement with the U.S. Food and Drug Administration (FDA) to develop “biosignature assay standards” that will serve to provide greater understanding of human diseases and speed the safe testing of new therapies. (An assay is a procedure for testing a biological sample, such as blood or biopsy, taken from an individual.) According to Raymond Woosley, MD, PhD, President and CEO of C-Path, “Biosignatures (multiple, combined tests and characteristics of patients) hold the key to understanding diseases and how best to facilitate their effective diagnosis and treatment.”

These efforts will be performed in collaboration with leading scientists and research organizations including The Biodesign Institute at Arizona State University (ASU), the International Genomics Consortium (IGC), the Arizona Cancer Center, University of Arizona (UA) Health Sciences Center, and the Translational Genomics Research Institute (TGen). Additionally, as required with SFAz-administered grants, C-Path will also leverage the $2.2 million award with additional in kind support from pharmaceutical companies. Ventana Medical System’s President, Hany Massarany said, “We are proud to work closely with C-Path in building a unique alliance within the Arizona bioscience community. This type of collaborative effort is key to advancing "personalized" medicine that uses genetics to match patients to therapies for the best results.”

“Utilizing the many resources that already exist in our State, this cooperative effort has the potential to breed many more Arizona-born success stories in the treatment of cancer and other debilitating diseases,” said William C. Harris, President and CEO of SFAz. “We thank the Governor for her support and dedication to science and innovation that shows the state is serious about moving ahead in the 21st century.”

*The funding is made available through the Governor’s discretionary funds from the federal American Recovery and Reinvestment Act of 2009.*

*This project was supported by the Governor’s Office of Economic Recovery and Science.*

###

**About Critical Path Institute (C-Path):** An independent, non-profit organization established in 2005, C-Path is committed to transformational improvement of the drug development process. An international leader in forming collaborations around this mission, C-Path has brought recognition to Arizona through first of its kind global programs and partnerships which currently include over 750 scientists from international government regulatory agencies, academia, patient advocacy organizations, and thirty major pharmaceutical companies. C-Path is
headquartered in Tucson, Arizona, with offices in Phoenix, Arizona, and Rockville, Maryland. For more information, visit [www.c-path.org](http://www.c-path.org).

**About Science Foundation Arizona:** Science Foundation Arizona (SFAz) is a 501(c)(3) non-profit organization initiated in 2006 by the Greater Phoenix Leadership Inc., Southern Arizona Leadership Council and the Flagstaff Forty in conjunction with the executive and legislative branches of state government. SFAz serves as a catalyst for high-wage, knowledge-based jobs and economic diversity through administration and strict oversight of research, development and education grants to public education and other non-profit research performing institutions. For more information, visit [www.sfaz.org](http://www.sfaz.org).